User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

Infront up-to-date–
news, dates, events



DKF 2021, 10. D-A-CH Kongress für Finanzinformationen
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2021 website.

19th COPS Usertreff
Exhibitions and Congresses

As in previous years, COPS invites to their annual COPS user meeting this year from 24 to 25 June 2021 at the Seehotel Rust in Rust on Neusiedlersee.

The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.

As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.

On site, our colleagues Catherine Hanek, Achim Beisswenger and Sebastian Ullrich will be available for a lively exchange of ideas.

You can find further information here...

 Latest news on markets, economy and companies


Business Wire



20.10.2020 GlobeNewswire: Idorsia announces the results of its rights offering in the context of the capital increase

Idorsia announces the results of its rights offering in the context of the

capital increase


• The capital increase by way of an at-market rights offering now moves

to the bookbuilding process for up to 7,974,681 shares



Allschwil, Switzerland – October 20, 2020

Idorsia Ltd (SIX: IDIA) today announced that in the context of its capital

increase by way of an at-market rights offering, rights have been exercised for

15,825,319 new shares, corresponding to 66.5% of the maximum number of up to

23,800,000 new shares offered in the rights offering.


The up to 7,974,681 shares not taken up by existing shareholders in the rights

offering are being offered to investors by way of a public offering in

Switzerland and to qualified investors by way of private placements in certain

jurisdictions outside Switzerland and the United States of America (the “United

States” or “US”) pursuant to Regulation S of the US Securities Act of 1933, as

amended (the “Securities Act”) and in the United States to qualified

institutional buyers as defined in Rule 144A of the Securities Act pursuant to

an exemption from the registration requirements of the Securities Act (the

“International Offering”).


Idorsia’s principal shareholders, Jean-Paul and Martine Clozel, have exercised

their rights in order to maintain their current shareholding of 28.4% in

Idorsia. They may also participate in the International Offering and

potentially increase their shareholding up to 30%.


The book for the International Offering is currently open. The offer price in

the rights offering and for the International Offering will be determined

following the end of the bookbuilding period. As contemplated in the offering

and listing prospectus, Idorsia intends to end the bookbuilding period earlier

than previously communicated: The close of the bookbuilding period as well as

the offer price are expected before the opening of SIX Swiss Exchange on

October 21, 2020.


The listing according to the International Reporting Standard of SIX Swiss

Exchange, first trading day, settlement and delivery of the new shares is

expected to be on October 23, 2020.


Notes to the editor


About Idorsia

Idorsia Ltd is reaching out for more - We have more ideas, we see more

opportunities and we want to help more patients. In order to achieve this, we

will develop Idorsia into one of Europe’s leading biopharmaceutical companies,

with a strong scientific core.


Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is

specialized in the discovery and development of small molecules, to transform

the horizon of therapeutic options. Idorsia has a broad portfolio of innovative

drugs in the pipeline, an experienced team, a fully-functional research center,

and a strong balance sheet – the ideal constellation to bringing R&D efforts to

business success.


Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June

2017 and has over 800 highly qualified specialists dedicated to realizing our

ambitious targets.


For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 (0) 58 844 10 10


This document is not an offer to sell or a solicitation of offers to purchase

or subscribe for securities. This document is not a prospectus within the

meaning of Article 652a of the Swiss Code of Obligations as such article was in

effect immediately prior to the entry into effect of the Swiss Financial

Services Act, nor is it a listing prospectus as defined in articles 27 et seqq.

of the listing rules of SIX Swiss Exchange AG or of any other stock exchange or

regulated trading venue in Switzerland nor is it a prospectus within the

meaning of the Swiss Financial Services Act nor a prospectus under any other

applicable laws. Copies of this document may not be sent to jurisdictions, or

distributed in or sent from jurisdictions, in which this is barred or

prohibited by law. The information contained herein shall not constitute an

offer to sell or the solicitation of an offer to buy, in any jurisdiction in

which such offer or solicitation would be unlawful prior to registration,

exemption from registration or qualification under the securities laws of any



A decision to invest in securities of Idorsia Ltd should be based exclusively

on the issue and listing prospectus published by Idorsia Ltd (the “Company”)

for such purpose. Copies of such issue and listing prospectus (and any

supplements thereto) are available free of charge from Credit Suisse AG,

Zurich, Switzerland (email: In addition,

copies of such issue and listing prospectus (and any supplements thereto) are

available free of charge in Switzerland from Idorsia Ltd, Hegenheimermattweg

91, 4123 Allschwil, (telephone number: +41 58 844 10 10; email:


This document is not for publication or distribution in the United States of

America (including its territories and possessions, any State of the United

States and the District of Columbia), Canada, Japan or Australia or any other

jurisdiction into which the same would be unlawful. This document does not

constitute an offer or invitation to subscribe for or purchase any securities

in such countries or in any other jurisdiction into which the same would be

unlawful. In particular, the document and the information contained herein

should not be distributed or otherwise transmitted into the United States of

America or to publications with a general circulation in the United States of

America. The securities referred to herein have not been and will not be

registered under the U.S. Securities Act of 1933, as amended (the “Securities

Act”), or the laws of any state, and may not be offered or sold in the United

States of America absent registration under or an exemption from registration

under the Securities Act. There will be no public offering of the securities in

the United States of America.


The information contained herein does not constitute an offer of securities to

the public in the United Kingdom. No prospectus offering securities to the

public will be published in the United Kingdom. This document is only being

distributed to and is only directed at (i) persons who are outside the United

Kingdom or (ii) to investment professionals falling within article 19(5) of the

Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the

“FSMA Order”) or (iii) persons falling within Articles 49(2)(a) to (d), “high

net worth companies, unincorporated associations, etc.” of the FSMA Order, and

(iv) persons to whom an invitation or inducement to engage in investment

activity within the meaning of Section 21 of the Financial Services and Markets

Act 2000 may otherwise be lawfully communicated or caused to be communicated

(all such persons together being referred to as “relevant persons”). The

securities are only available to, and any invitation, offer or agreement to

subscribe, purchase or otherwise acquire such securities will be engaged in

only with, relevant persons. Any person who is not a relevant person should not

act or rely on this document or any of its contents.


In any member state of the European Economic Area and the United Kingdom (each

an “EEA Member State”) this document is only addressed to qualified investors

in that EEA Member State within the meaning of the Regulation (EU) 2017/1129.

Information to Distributors: Solely for the purposes of the product governance

requirements contained within: (a) EU Directive 2014/65/EU on markets in

financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of

Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)

local implementing measures (together, the “MiFID II Product Governance

Requirements”), and disclaiming all and any liability, whether arising in tort,

contract or otherwise, which any “manufacturer” (for the purposes of the MiFID

II Product Governance Requirements) may otherwise have with respect thereto,

the Shares have been subject to a product approval process by each underwriter

established in the EEA, which has determined that the Shares are:

(i) compatible with an end target market of retail investors and investors who

meet the criteria of professional clients and eligible counterparties, each as

defined in MiFID II; and (ii) eligible for distribution through all

distribution channels as are permitted by MiFID II (the “Target Market

Assessment”). Notwithstanding the Target Market Assessment, Distributors should

note that: the price of the Shares may decline and investors could lose all or

part of their investment; the Shares offer no guaranteed income and no capital

protection; and an investment in the Shares is compatible only with investors

who do not need a guaranteed income or capital protection, who (either alone or

in conjunction with an appropriate financial or other adviser) are capable of

evaluating the merits and risks of such an investment and who have sufficient

resources to be able to bear any losses that may result therefrom.


The Target Market Assessment is without prejudice to the requirements of any

contractual, legal or regulatory selling restrictions in relation to the

offering Furthermore, it is noted that, notwithstanding the Target Market

Assessment, the underwriters established in the EEA will only procure investors

who meet the criteria of professional clients and eligible counterparties. For

the avoidance of doubt, the Target Market Assessment does not constitute: (a)

an assessment of suitability or appropriateness for the purposes of MiFID II;

or (b) a recommendation to any investor or group of investors to invest in, or

purchase, or take any other action whatsoever with respect to the Shares. Each

distributor is responsible for undertaking its own target market assessment in

respect of the Shares and determining appropriate distribution channels.


This publication may contain specific forward-looking statements, e.g.

statements including terms like “believe”, “assume”, “expect”, “forecast”,

“project”, “may”, “could”, “might”, “will” or similar expressions. Such

forward-looking statements are subject to known and unknown risks,

uncertainties and other factors which may result in a substantial divergence

between the actual results, financial situation, development or performance of

Idorsia Ltd and those explicitly or implicitly presumed in these statements.

Against the background of these uncertainties, readers should not rely on

forward-looking statements. Idorsia Ltd assumes no responsibility to up-date

forward-looking statements or to adapt them to future events or developments.

Except as required by applicable law, Idorsia Ltd has no intention or

obligation to update, keep updated or revise this publication or any parts

thereof (including any forward-looking statement) following the date hereof.







Anhang Medienmitteilung PDF



Subscribe to our free newsletter and you will receive the latest information about our products and solutions.